MBD2

Across TCGA pan-cancer cohorts, MBD2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MBD2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where MBD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MBD2 is over-expressed in tumor.

LSCC, LUAD, and COAD are the cancer types where MBD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MBD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.438	<.001	8	view →
LUAD	Female	All	+0.162	<.001	8	view →
COAD	All	All	+0.095	.001	4	view →
HNSC	All	All	+0.090	.014	4	view →
OV	All	All	+0.326	.006	2	view →
CCRCC	Male	All	+0.090	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MBD2–LSCC

Open the LSCC breakdown →